AbbVie Inc. $ABBV Shares Sold by LaFleur & Godfrey LLC

Key Points

• LaFleur & Godfrey LLC reduced its AbbVie stake by 4.8% in the third quarter, selling 3,545 shares and retaining 69,574 shares valued at approximately $18.2 million. Institutional investors collectively own 70.23% of ABBV.
• AbbVie reported quarterly earnings and revenue above analyst expectations, with earnings per share of $3.65 and revenue of $16.99 billion, up 10.2% year over year. Analysts maintain a “Moderate Buy” consensus rating with an average price target of $279.86.
• The company declared a quarterly dividend of $1.73 per share, equivalent to an annualized $6.92 and a 2.4% yield. Investors remain focused on growth from Skyrizi, Rinvoq and the potential approval of oncology drug candidate etentamig, while valuation and future competition remain concerns.

LaFleur & Godfrey LLC cut its stake in AbbVie Inc. (NYSE:ABBV - Free Report) by 4.8% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 69,574 shares of the company's stock after selling 3,545 shares during the quarter. AbbVie comprises about 2.2% of LaFleur & Godfrey LLC's holdings, making the stock its 13th largest position. LaFleur & Godfrey LLC's holdings in AbbVie were worth $18,200,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. State Street Corp boosted its stake in AbbVie by 1.7% in the 2nd quarter. State Street Corp now owns 82,596,748 shares of the company's stock worth $20,784,646,000 after purchasing an additional 1,379,232 shares during the period. Corient Private Wealth LP purchased a new position in AbbVie during the 2nd quarter valued at about $559,736,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of AbbVie by 0.7% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 14,267,697 shares of the company's stock valued at $3,590,323,000 after buying an additional 106,091 shares during the period. Legal & General Group Plc bought a new stake in shares of AbbVie during the second quarter valued at about $2,905,952,000. Finally, Deutsche Bank AG lifted its holdings in shares of AbbVie by 13.0% in the second quarter. Deutsche Bank AG now owns 10,772,949 shares of the company's stock worth $2,710,905,000 after buying an additional 1,241,587 shares in the last quarter. 70.23% of the stock is currently owned by institutional investors.

AbbVie Trading Down 0.1%

Shares of NYSE ABBV opened at $286.10 on Thursday. AbbVie Inc. has a 12 month low of $190.75 and a 12 month high of $291.40. The firm has a market capitalization of $505.47 billion, a price-to-earnings ratio of 80.82, a PEG ratio of 1.30 and a beta of 0.24. The business has a 50-day moving average of $268.20 and a 200-day moving average of $236.51.

AbbVie (NYSE:ABBV - Get Free Report) last posted its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, topping the consensus estimate of $3.61 by $0.04. The company had revenue of $16.99 billion for the quarter, compared to analysts' expectations of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. AbbVie's revenue for the quarter was up 10.2% compared to the same quarter last year. During the same period in the prior year, the business earned $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, analysts predict that AbbVie Inc. will post 13.92 earnings per share for the current year.

AbbVie Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date of this dividend is Thursday, October 15th. AbbVie's dividend payout ratio is currently 195.48%.

Analyst Ratings Changes

ABBV has been the subject of a number of analyst reports. Scotiabank raised their price objective on shares of AbbVie from $280.00 to $320.00 and gave the company an "outperform" rating in a research report on Tuesday, October 6th. Wells Fargo & Company increased their target price on shares of AbbVie from $295.00 to $300.00 and gave the stock an "overweight" rating in a research note on Monday, August 17th. Cantor Fitzgerald raised their price target on shares of AbbVie from $285.00 to $290.00 and gave the company an "overweight" rating in a report on Thursday, October 8th. Rothschild & Co Redburn boosted their price target on shares of AbbVie from $284.00 to $285.00 and gave the company a "buy" rating in a research report on Tuesday, August 4th. Finally, JPMorgan Chase & Co. upped their price target on shares of AbbVie from $285.00 to $300.00 and gave the stock an "overweight" rating in a report on Thursday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and six have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $279.86.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie submitted a Biologics License Application to the FDA for etentamig, a monthly-dosed BCMA x CD3 bispecific antibody for adults with relapsed or refractory multiple myeloma. The Phase 3 CERVINO study reportedly delivered statistically significant improvements in overall response rate and progression-free survival versus standard therapies, adding a potential growth product to AbbVie’s oncology pipeline. AbbVie Submits BLA for Etentamig
• Positive Sentiment: AbbVie’s growth drivers remain in focus. Skyrizi and Rinvoq are expected to help offset Humira’s decline, while the FDA’s approval of a subcutaneous induction option for Skyrizi in Crohn’s disease could improve convenience and broaden adoption through at-home treatment. Skyrizi Crohn’s Disease Approval
• Neutral Sentiment: Investors are preparing for AbbVie’s third-quarter results, with attention on Skyrizi and Rinvoq sales, expense trends, updated guidance, and the sustainability of earnings growth. The company previously reported quarterly revenue and adjusted earnings above consensus expectations.
• Negative Sentiment: Analysts continue to debate whether ABBV is fully valued after a strong rally. Its elevated valuation leaves less room for disappointment, while rising expenses, softer estimates, and intensifying competition could pressure near-term results. AbbVie Patent Cliff Analysis
• Negative Sentiment: The company’s dividend appeal faces a longer-term test as investors seek evidence that Skyrizi and Rinvoq can replace lost Humira revenue and support continued payout growth. High Treasury yields also make income-oriented stocks compete harder for investor capital.

Insiders Place Their Bets

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of AbbVie stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the completion of the sale, the executive vice president owned 74,430 shares of the company's stock, valued at $18,607,500. The trade was a 30.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.06% of the stock is owned by insiders.

AbbVie Company Profile

AbbVie Inc NYSE: ABBV is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company's key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.